Drug Discovery

OptiBiotix Health signs manufacturing and supply deal in India with Akums

OptiBiotix Health has entered into a five year agreement with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply products featuring OptiBiotix's cholesterol and blood pressure reducing strain LPLDL in India.

Surface Pharmaceuticals secures $20m funding from Flying L Partners

Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.

Zymeworks, Daiichi Sankyo expand immuno-oncology partnership

Zymeworks and Daiichi Sankyo have entered into a new license agreement, building upon their cross-licensing and collaboration agreement signed in 2016.

Lilly to acquire AurKa Pharma in $575m deal

Eli Lilly and Company (Lilly) has agreed to acquire Canadian cancer drug developer AurKa Pharma from TVM Capital Life Science in a deal worth $575m.

Lilly to buy immuno-oncology firm Armo BioSciences for $1.6bn

Eli Lilly and Company (Lilly) has agreed to acquire Armo BioSciences, a US-based late-stage immuno-oncology company, for about $1.6bn in an all-cash deal.

Escient Pharmaceuticals raises $40m

Escient Pharmaceuticals has been launched with $40m Series A financing to advance G protein-coupled receptor (GPCR)-targeted drugs to address serious, unserved medical needs.

Forma Therapeutics, University of Oxford partner to advance DUB inhibitors development

Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.

Amneal, Impax form Amneal Pharmaceuticals

Amneal Pharmaceuticals and Impax Laboratories have completed their business combination to form Amneal Pharmaceuticals.

InDex Pharmaceuticals develops oral formulation of Cobitolimod

InDex Pharmaceuticals Holding has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract.